对高级非小细胞肺癌的免疫疗法结合的抗血管原剂:系统性审查和元分析

Heng Lin1, Chenhui Ma2, Aihong Zhong1

  • 1Department of Oncology, Fuzhou Pulmonary Hospital of Fujian, Fuzhou, Fujian, 350008, China.

概括

抗血管生成和免疫疗法的联合疗法显示,在晚期非小细胞肺癌 (NSCLC) 中具有有前途的抗瘤活性. 这一元分析证实了有利的疗效和安全性,为NSCLC治疗提供了指导.

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K